GRACE KIM to Idiopathic Pulmonary Fibrosis
This is a "connection" page, showing publications GRACE KIM has written about Idiopathic Pulmonary Fibrosis.
Connection Strength
1.961
-
Minimum clinically important difference in Quantitative Lung Fibrosis score associated with all-cause mortality in idiopathic pulmonary fibrosis: subanalysis from two phase II trials of pamrevlumab. BMJ Open. 2025 May 12; 15(5):e094559.
Score: 0.825
-
Extent of lung fibrosis is of greater prognostic importance than HRCT pattern in patients with progressive pulmonary fibrosis: data from the ILD-PRO registry. Respir Res. 2025 Feb 28; 26(1):73.
Score: 0.203
-
Bexotegrast in Patients with Idiopathic Pulmonary Fibrosis: The INTEGRIS-IPF Clinical Trial. Am J Respir Crit Care Med. 2024 08 15; 210(4):424-434.
Score: 0.196
-
Pulmonary Fibrosis Stakeholder Summit: A Joint NHLBI, Three Lakes Foundation, and Pulmonary Fibrosis Foundation Workshop Report. Am J Respir Crit Care Med. 2024 02 15; 209(4):362-373.
Score: 0.189
-
Bexotegrast in people with idiopathic pulmonary fibrosis (IPF): a plain language summary of publication of the INTEGRIS-IPF study. Ther Adv Respir Dis. 2024 Jan-Dec; 18:17534666241287307.
Score: 0.188
-
Quantitative interstitial lung disease scores in idiopathic inflammatory myopathies: longitudinal changes and clinical implications. Rheumatology (Oxford). 2023 11 02; 62(11):3690-3699.
Score: 0.186
-
Automated quantification system predicts survival in rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford). 2022 11 28; 61(12):4702-4710.
Score: 0.174